Received: 10 September 2018
Accepted: 17 December 2018
First Online: 10 January 2019
Ethics approval and consent to participate
: Our study protocol was approved by the Kyoto University Graduate School and Faculty of Medicine, Ethics Committee. For this type of study, formal consent is not required.
: Not applicable.
: All of the authors except one report they have no conflict of interest to disclose. KK receives consulting fees or speakers honoraria from: Takeda Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., AbbVie Inc., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., Santen Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Olympus Corporation, Shin Nippon Biomedical Laboratories, LTD., and Japan Medical Data Center Co., Ltd.; research funds from: Olympus Corporation, Sumitomo Dainippon Pharma Co., Ltd., Bayer Yakuhin Ltd., Stella Pharma Corporation, Novartis Pharma K.K., CMIC Co., Ltd., Amgen Astellas BioPharma K.K., Suntory Beverage & Food Ltd., and Medical Platform Co., Ltd.; and holds stocks in: School Health Record Center Co., Ltd. and Real World Data Co., Ltd.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.